For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $98.49 in the prior trading day, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) closed at $100.3, up 1.84%. In other words, the price has increased by $1.84 from its previous closing price. On the day, 1.16 million shares were traded. RYTM stock price reached its highest trading level at $102.2 during the session, while it also had its lowest trading level at $95.27.
Ratios:
Our goal is to gain a better understanding of RYTM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.53 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 1.75 whereas as Long-Term Debt/Eq ratio is at 1.71.
On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $97.
On July 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $88.Leerink Partners initiated its Outperform rating on July 07, 2025, with a $88 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 07 ’25 when PAMELA CRAMER bought 19,351 shares for $98.49 per share.
Shulman Joseph sold 9,748 shares of RYTM for $1,123,398 on Oct 30 ’25. The Chief Technical Officer now owns 8,509 shares after completing the transaction at $115.24 per share. On Oct 28 ’25, another insider, Shulman Joseph, who serves as the Chief Technical Officer of the company, sold 2,815 shares for $115.01 each. As a result, the insider received 323,750 and left with 8,509 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 6693626368 and an Enterprise Value of 6537544192. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.40 while its Price-to-Book (P/B) ratio in mrq is 44.94. Its current Enterprise Value per Revenue stands at 37.5 whereas that against EBITDA is -35.384.
Stock Price History:
The Beta on a monthly basis for RYTM is 1.99, which has changed by 0.5294297 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $116.00, while it has fallen to a 52-week low of $45.90. The 50-Day Moving Average of the stock is -2.62%, while the 200-Day Moving Average is calculated to be 31.71%.
Shares Statistics:
The stock has traded on average 612.73K shares per day over the past 3-months and 798830 shares per day over the last 10 days, according to various share statistics. A total of 66.68M shares are outstanding, with a floating share count of 61.70M. Insiders hold about 7.54% of the company’s shares, while institutions hold 97.88% stake in the company. Shares short for RYTM as of 1760486400 were 5574246 with a Short Ratio of 9.10, compared to 1757894400 on 5220961. Therefore, it implies a Short% of Shares Outstanding of 5574246 and a Short% of Float of 10.76.
Earnings Estimates
The dynamic stock of Rhythm Pharmaceuticals Inc (RYTM) is currently attracting attention from 5.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.41 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$2.7 and -$3.32 for the fiscal current year, implying an average EPS of -$3.05. EPS for the following year is -$2.09, with 9.0 analysts recommending between -$0.63 and -$3.42.
Revenue Estimates
10 analysts predict $55.08M in revenue for. The current quarter. It ranges from a high estimate of $57M to a low estimate of $52.8M. As of. The current estimate, Rhythm Pharmaceuticals Inc’s year-ago sales were $41.83MFor the next quarter, 10 analysts are estimating revenue of $56.39M. There is a high estimate of $62.8M for the next quarter, whereas the lowest estimate is $50M.
A total of 13 analysts have provided revenue estimates for RYTM’s current fiscal year. The highest revenue estimate was $192.55M, while the lowest revenue estimate was $185.3M, resulting in an average revenue estimate of $187.92M. In the same quarter a year ago, actual revenue was $130.13MBased on 14 analysts’ estimates, the company’s revenue will be $296.18M in the next fiscal year. The high estimate is $360.7M and the low estimate is $265M.
